RxDoctor Payments Data

Heather Williamson, NP

Family · Milledgeville, GANPI 1104234723

Payments from drug & device makers

$1,511in general payments, 2019–2025

Across 72 payments — averaging $20.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$701
  • Madrigal Pharmaceuticals$268
  • Ardelyx, Inc.$180
  • Ferring Pharmaceuticals Inc.$91
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$74
  • Sanofi$55
  • plus $142 from 5 others

What the payments were for

  • Food & beverage$1,511100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,511 in reported general payments places this provider in the 75th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$31,548
Medicare patients
246
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide92$60,766
ClenpiqSod Picosulf/Mag Ox/Citric Ac157$27,172
Mesalamine32$8,573
Dexlansoprazole DrDexlansoprazole30$7,943
Omeprazole228$3,363
Famotidine192$3,034
Pantoprazole Sodium244$2,888
Mesalamine ErMesalamine15$2,825
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl136$1,829
Sucralfate45$1,658
Esomeprazole Magnesium24$1,474
Tetracycline Hcl11$1,215
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl77$1,210
Lubiprostone14$1,096
Dicyclomine Hcl51$1,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$701$60,76692 claims
Ferring Pharmaceuticals Inc.Clenpiq$91$27,172157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,258 family providers in Georgia.

Other family in Milledgeville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →